269 related articles for article (PubMed ID: 33315881)
1. Presence of anti-nuclear antibodies is a risk factor for the appearance of anti-drug antibodies during infliximab or adalimumab therapy in patients with rheumatoid arthritis.
Mori A; Saito T; Takahashi M; Shibata M; Tsuji G; Hatachi S; Takahashi S; Kumagai S
PLoS One; 2020; 15(12):e0243729. PubMed ID: 33315881
[TBL] [Abstract][Full Text] [Related]
2. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.
Moots RJ; Xavier RM; Mok CC; Rahman MU; Tsai WC; Al-Maini MH; Pavelka K; Mahgoub E; Kotak S; Korth-Bradley J; Pedersen R; Mele L; Shen Q; Vlahos B
PLoS One; 2017; 12(4):e0175207. PubMed ID: 28448562
[TBL] [Abstract][Full Text] [Related]
3. Switching from an anti-TNF monoclonal antibody to soluble TNF-receptor yields better results than vice versa: An observational retrospective study of 72 rheumatoid arthritis switchers.
Lequerré T; Farran É; Ménard JF; Kozyreff-Meurice M; Vandhuick T; Tharasse C; Pouplin S; Daragon A; Le Loët X; Varin R; Vittecoq O
Joint Bone Spine; 2015 Oct; 82(5):330-7. PubMed ID: 25864942
[TBL] [Abstract][Full Text] [Related]
4. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.
Oladapo A; Barner JC; Lawson KA; Novak S; Rascati KL; Richards KM; Harrison DJ
J Manag Care Spec Pharm; 2014 Jul; 20(7):657-67. PubMed ID: 24967519
[TBL] [Abstract][Full Text] [Related]
5. Retention rates of adalimumab, etanercept, and infliximab as first- or second-line biotherapies for spondyloarthritis patients in daily practice in Auvergne (France).
Soubrier M; Pereira B; Fan A; Frayssac T; Couderc M; Malochet-Guinamand S; Mathieu S; Tatar Z; Tournadre A; Dubost JJ
Int J Rheum Dis; 2018 Nov; 21(11):1986-1992. PubMed ID: 30168265
[TBL] [Abstract][Full Text] [Related]
6. Persistence and dose escalation of tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis.
Cannon GW; DuVall SL; Haroldsen CL; Caplan L; Curtis JR; Michaud K; Mikuls TR; Reimold A; Collier DH; Harrison DJ; Joseph GJ; Sauer BC
J Rheumatol; 2014 Oct; 41(10):1935-43. PubMed ID: 25128516
[TBL] [Abstract][Full Text] [Related]
7. Retention rates of adalimumab, etanercept and infliximab as first-line biotherapy agent for rheumatoid arthritis patients in daily practice - Auvergne experience.
Soubrier M; Pereira B; Frayssac T; Fan A; Couderc M; Malochet-Guinamand S; Mathieu S; Tatar Z; Tournadre A; Dubost JJ
Int J Rheum Dis; 2018 Nov; 21(11):1924-1932. PubMed ID: 28901727
[TBL] [Abstract][Full Text] [Related]
8. Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study.
Balsa A; Sanmarti R; Rosas J; Martin V; Cabez A; Gómez S; Montoro M
Rheumatology (Oxford); 2018 Apr; 57(4):688-693. PubMed ID: 29365183
[TBL] [Abstract][Full Text] [Related]
9. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register.
Lie E; Lindström U; Zverkova-Sandström T; Olsen IC; Forsblad-d'Elia H; Askling J; Kapetanovic MC; Kristensen LE; Jacobsson LTH
Ann Rheum Dis; 2017 Sep; 76(9):1515-1521. PubMed ID: 28254789
[TBL] [Abstract][Full Text] [Related]
10. Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study.
Yukawa N; Fujii T; Kondo-Ishikawa S; Yoshifuji H; Kawabata D; Nojima T; Ohmura K; Usui T; Mimori T
Arthritis Res Ther; 2011; 13(6):R213. PubMed ID: 22192852
[TBL] [Abstract][Full Text] [Related]
11. No Correlation between Anti-drug Antibodies and Therapeutic Response in Tunisian Patients with Chronic Inflammatory Diseases Treated by TNF Blockers.
Bouden S; Laadhar L; Soua J; Ben Messaoud M; Rouached L; Ayadi I; Saidane O; Ben Tekaya A; Mahmoud I; Rekik S; Srairi HS; Tekaya R; Bellakhal S; Fekih M; Abdelmoula L; Kallel M
Curr Rheumatol Rev; 2024; 20(4):435-443. PubMed ID: 38314598
[TBL] [Abstract][Full Text] [Related]
12. Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNFalpha blocking agents in rheumatoid arthritis.
Benucci M; Saviola G; Baiardi P; Cammelli E; Manfredi M
Clin Rheumatol; 2008 Jan; 27(1):91-5. PubMed ID: 17929076
[TBL] [Abstract][Full Text] [Related]
13. Impact of three anti-TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients.
Bacquet-Deschryver H; Jouen F; Quillard M; Ménard JF; Goëb V; Lequerré T; Mejjad O; Daragon A; Tron F; Le Loët X; Vittecoq O
J Clin Immunol; 2008 Sep; 28(5):445-55. PubMed ID: 18587633
[TBL] [Abstract][Full Text] [Related]
14. Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis.
Quistrebert J; Hässler S; Bachelet D; Mbogning C; Musters A; Tak PP; Wijbrandts CA; Herenius M; Bergstra SA; Akdemir G; Johannesson M; Combe B; Fautrel B; Chollet-Martin S; Gleizes A; Donnellan N; Deisenhammer F; Davidson J; Hincelin-Mery A; Dönnes P; Fogdell-Hahn A; De Vries N; Huizinga T; Abugessaisa I; Saevarsdottir S; Hacein-Bey-Abina S; Pallardy M; Broët P; Mariette X;
Semin Arthritis Rheum; 2019 Jun; 48(6):967-975. PubMed ID: 30420245
[TBL] [Abstract][Full Text] [Related]
15. Optimizing biological treatment in rheumatoid arthritis with the aid of therapeutic drug monitoring.
Eng GP
Dan Med J; 2016 Nov; 63(11):. PubMed ID: 27808043
[TBL] [Abstract][Full Text] [Related]
16. BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors.
Hernández-Breijo B; Navarro-Compán V; Plasencia-Rodríguez C; Parodis I; Gehin JE; Martínez-Feito A; Novella-Navarro M; Mezcua A; Warren DJ; Nozal P; Pascual-Salcedo D; Balsa A
Sci Rep; 2021 Jun; 11(1):11632. PubMed ID: 34079038
[TBL] [Abstract][Full Text] [Related]
17. An examination of the mechanisms involved in secondary clinical failure to adalimumab or etanercept in inflammatory arthropathies.
Bandrés Ciga S; Salvatierra J; López-Sidro M; García-Sánchez A; Durán R; Vives F; Raya-Álvarez E
J Clin Rheumatol; 2015 Apr; 21(3):115-9. PubMed ID: 25807089
[TBL] [Abstract][Full Text] [Related]
18. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
[TBL] [Abstract][Full Text] [Related]
19. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers.
Gonnet-Gracia C; Barnetche T; Richez C; Blanco P; Dehais J; Schaeverbeke T
Clin Exp Rheumatol; 2008; 26(3):401-7. PubMed ID: 18578960
[TBL] [Abstract][Full Text] [Related]
20. Effect of serum anti-tumour necrosis factor (TNF) drug trough concentrations and antidrug antibodies (ADAb) to further anti-TNF short-term effectiveness after switching in rheumatoid arthritis and axial spondyloarthritis.
Vincent FB; Pavy S; Krzysiek R; Lequerré T; Sellam J; Taoufik Y; Mariette X; Miceli-Richard C
Joint Bone Spine; 2016 Oct; 83(5):595-7. PubMed ID: 27066773
[No Abstract] [Full Text] [Related]
[Next] [New Search]
